Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic immune-mediated disease from a group of spondyloarthritis, which is characterized by damage to the musculoskeletal system with a wide range of different clinical manifestations and is usually associated with psoriasis. Activation of the interleukin (IL) 23/IL17...
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | Russian |
| Έκδοση: |
IMA-PRESS LLC
2020-11-01
|
| Σειρά: | Современная ревматология |
| Θέματα: | |
| Διαθέσιμο Online: | https://mrj.ima-press.net/mrj/article/view/1085 |